Phase 3 Clinical Trials With Primary Completion Dates in February 2021
This is a list of Phase 3 trials with primary completion dates in February 2021 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| FGEN | FibroGen, Inc. | 2021-02-01 | Phase 3 | NCT04484857 | Study of Roxadustat Conversion in Subjects Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Patients |
| MESO | Mesoblast Limited | 2021-02-01 | Phase 3 | NCT04371393 | MSCs in COVID-19 ARDS |
| RVVTF | Revive Therapeutics Ltd. | 2021-02-01 | Phase 3 | NCT04504734 | Bucillamine in Treatment of Patients With COVID-19 |